Navigation Links
Joe Martin Appointed CEO of Milestone Scientific and New Executive Member of the Board of Directors
Date:12/12/2007

Leonard Osser, Former CEO, Will Continue Serving as Chairman of the Board

LIVINGSTON, N.J., Dec. 12 /PRNewswire-FirstCall/ -- Milestone Scientific, Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced that the Board of Directors has named Joe Martin, Chief Executive Officer of the Company's medical division, as the new CEO of the Company and a member of its Board of Directors, effective January 1, 2008. As CEO, Martin replaces Leonard Osser, who will continue serving as the Chairman of the Board.

"We are very pleased that Joe has agreed to become Milestone's CEO and the newest addition to our Board of Directors," stated Osser. "Since Joe's arrival, he has been instrumental in directing and effecting positive changes in Milestone's operations. Given our longstanding belief that Milestone's ultimate success will stem from maximizing opportunities for our patented CompuFlo(R) technology in the medical arena, coupled with Joe's level of experience and expertise earned as an executive at Bayer and Abbott, there is simply no question that he is the ideal choice to assume leadership of our Company."

Martin has served as CEO of Milestone Medical since joining the Company in May 2007. Previously, he served as President of the Diabetes Care Division (DCD) at Bayer Healthcare, as well as a member of the Bayer HealthCare Executive Committee. From 1992 through 2005, Martin rose through the ranks at Bayer in managerial posts that included Senior Vice President and General Manager, Self-Testing Business Segment; Country Manager -- United Kingdom and Ireland; and Vice President, Marketing -- Immunodiagnostic Business Unit. From 1980 until 1992, Martin held various sales, marketing and general management roles of increasing responsibility, both domestically and internationally, at Abbott Laboratories -- Diagnostic Division. Martin is a graduate of the University of Houston, where he earned a Bachelors of Business Administration degree in Marketing and Accounting. Martin is the Past President of the Biomedical Marketing Association and served on the Board of Directors of Life Treatment Centers in South Bend, Indiana.

Commenting on his new appointment, Martin noted, "As I see it, working towards having Milestone's CompuFlo technology globally recognized and adopted as a key enabler of a wide range of innovative medical and extra-medical applications is my most important directive as the Company's new CEO. However, I also understand and appreciate that we must build and maintain a highly productive, revenue-producing business platform that can and will support our more ambitious growth strategies. As such, I'm looking forward to advancing the important progress that Milestone has made with the commercialization of the STA System in the worldwide dental industry, while also capitalizing on exciting product development opportunities we are pursuing within the medical marketplace."

About Milestone Scientific, Inc.

Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company's IP platform and product development strategy is its patented CompuFlo(R) technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The Single Tooth Anesthesia (STA(TM)) computer-controlled local anesthesia delivery system which uses this technology provides dentists with audible and visual signals as to in-tissue pressure. Milestone's existing painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company's web site found at http://www.milesci.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of the Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report on Form 10-KSB for the year ended December 31, 2006. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

FOR MORE INFORMATION, PLEASE CONTACT:

Elite Financial Communications Group, LLC

Dodi Handy, President and CEO, or

Daniel Conway, Chief Strategist

407-585-1080 or via email at mlss@efcg.net


'/>"/>
SOURCE Milestone Scientific, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Purple: The Hottest Color for Fall in Shoes, Handbags and Martinis
2. DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer
3. Eric Rowinsky, M.D. and Martin Cannon Join Tapestry Board of Directors
4. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
5. William Moore Appointed to IRIDEX Board of Directors
6. Roy Jakobs Appointed Elsevier Managing Director, A&G Sales and Customer Marketing
7. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
8. Theodore A. Boutacoff Appointed President & CEO of IRIDEX
9. James B. Hawkins Appointed to IRIDEX Board of Directors
10. Bryan R. Rogers Appointed President of Far West Division
11. Catholic Health Association Disappointed by Failure to Override SCHIP Veto
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... ... April 30, 2016 , ... Create ... Abstract users can distort and manipulate three-dimensional shapes with ease all within ... ranks, point, lines, polygons, polygon texture animation, opacity texture animation, overall shape texture ...
(Date:4/30/2016)... , ... April 30, 2016 ... ... CBC News on April 4th, 2016 questioned the use of the HyProCure ... EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, ...
(Date:4/29/2016)... ... April 29, 2016 , ... In an article published April ... enthusiasm for Botox and lip injections, which she underwent in order to feel more ... Music and Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members of the ... signature of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. ... a 70% tax credit to individuals and corporations which donate directly to a “rural ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Coast Dental ... 16, 2016, at its new location in the Exchange Furniture Mall at 112 Vilseck ... for a 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 2016 Automation is one of ... to the growing demands for productivity in speed, accuracy, ... systems are already adept of a wide range of ... manual labor. Instrumentation continues to evolve, and is poised ... a few years ago. Originally used mostly by the ...
(Date:4/28/2016)... April 28, 2016  While Abbott,s announced purchase ... company,s valve repair and stent business, healthcare research ... Abbott more firmly into patient monitoring.  Kalorama said ... growing device areas, with double-digit growth expected the ... Advanced Remote Patient Monitoring . Abbott ...
(Date:4/28/2016)... April 28, 2016  Marking its one year ... and ovarian cancer risk test, Color Genomics ... genes that highly impact the most common hereditary ... the Color Test analyzes hereditary cancer risks for ... uterine cancers. The Color Test is physician ordered ...
Breaking Medicine Technology: